XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -65.75%549M | -133.12%-156M | 6.94%308M | -44.66%140M | -56.59%257M | 24.84%1.6B | 12.41%471M | -0.69%288M | -21.67%253M | 134.92%592M |
Net income from continuing operations | 40.58%433M | 288.25%945M | -148.47%-664M | -194.17%-339M | 153.37%491M | -83.35%308M | -146.57%-502M | 164.99%1.37B | -68.34%360M | -4.31%-920M |
Operating gains losses | -3,112.50%-241M | -15,900.00%-158M | ---- | 133.33%7M | 850.00%15M | 233.33%8M | 120.00%1M | 450.00%7M | 400.00%3M | -200.00%-2M |
Depreciation and amortization | -5.96%1.26B | -24.94%292M | -2.19%313M | -4.59%312M | 12.75%345M | 13.83%1.34B | 25.89%389M | 11.11%320M | 14.34%327M | 3.38%306M |
Deferred tax | 267.50%67M | 192.75%64M | -135.00%-7M | 81.25%-3M | -48.00%13M | -166.67%-40M | -72.50%-69M | 225.00%20M | -139.02%-16M | --25M |
Other non cash items | -206.55%-843M | -377.71%-1.28B | 145.89%665M | 181.87%307M | -148.94%-532M | 84.82%-275M | 144.08%462M | -146.43%-1.45B | 64.69%-375M | 21.18%1.09B |
Change In working capital | -131.85%-129M | -107.21%-16M | -16.28%36M | -79.37%-113M | -123.15%-47M | 493.20%405M | 50.00%222M | 216.22%43M | 42.20%-63M | 275.00%203M |
-Change in receivables | ---- | ---- | ---- | ---- | ---- | 298.15%535M | ---- | ---- | ---- | ---- |
-Change in payables and accrued expense | ---- | ---- | ---- | ---- | ---- | -129.14%-51M | ---- | ---- | ---- | ---- |
-Change in other working capital | ---- | ---- | -16.28%36M | -79.37%-113M | -123.15%-47M | -887.50%-79M | -207.82%-262M | 216.22%43M | ---63M | 269.17%203M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -65.75%549M | -133.12%-156M | 6.94%308M | -44.66%140M | -56.59%257M | 24.84%1.6B | 12.41%471M | -0.69%288M | -21.67%253M | 134.92%592M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 34.68%-665M | 80.56%-125M | -122.64%-118M | 46.32%-51M | -63.44%-371M | -37.94%-1.02B | -278.24%-643M | 76.02%-53M | 46.33%-95M | -33.53%-227M |
Net PPE purchase and sale | 7.68%-949M | 40.54%-311M | 12.43%-162M | -25.95%-199M | -70.99%-277M | -21.37%-1.03B | -134.53%-523M | 11.90%-185M | 35.77%-158M | 3.57%-162M |
Net business purchase and sale | 247.03%297M | 260.53%183M | --0 | --0 | --0 | -320.83%-202M | ---114M | 91.67%-4M | ---3M | ---81M |
Net investment purchase and sale | ---- | ---- | 177.42%86M | -16.50%86M | ---- | --134M | --0 | --31M | --103M | ---- |
Net other investing changes | -116.67%-13M | 150.00%3M | -140.00%-42M | 267.57%62M | -687.50%-94M | -50.32%78M | -111.32%-6M | 183.78%105M | -153.62%-37M | 900.00%16M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 34.68%-665M | 80.56%-125M | -122.64%-118M | 46.32%-51M | -63.44%-371M | -37.94%-1.02B | -278.24%-643M | 76.02%-53M | 46.33%-95M | -33.53%-227M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 130.19%192M | 13.48%303M | 46.45%-166M | 64.50%-82M | 137.85%137M | -58.21%-636M | 160.68%267M | -1,837.50%-310M | -621.88%-231M | -520.93%-362M |
Net issuance payments of debt | 296.22%467M | -32.02%397M | 18.37%-160M | 128.70%99M | 146.62%131M | -136.79%-238M | 366.67%584M | -197.51%-196M | -172.63%-345M | -247.89%-281M |
Net common stock issuance | --0 | --0 | --0 | --0 | ---- | --251M | --0 | --0 | --251M | ---- |
Cash dividends paid | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Net other financing activities | 57.63%-275M | 70.35%-94M | 94.74%-6M | -32.12%-181M | 107.41%6M | 33.16%-649M | -121.68%-317M | 47.47%-114M | 72.98%-137M | 22.12%-81M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 130.19%192M | 13.48%303M | 46.45%-166M | 64.50%-82M | 137.85%137M | -58.21%-636M | 160.68%267M | -1,837.50%-310M | -621.88%-231M | -520.93%-362M |
Net cash flow | ||||||||||
Beginning cash position | -2.34%627M | 20.66%619M | 3.19%614M | -2.74%639M | -2.34%627M | 22.29%642M | -37.59%513M | -24.68%595M | -5.33%657M | 22.29%642M |
Current changes in cash | 249.02%76M | -76.84%22M | 132.00%24M | 109.59%7M | 666.67%23M | -135.42%-51M | 149.74%95M | -241.51%-75M | -164.04%-73M | -98.21%3M |
Effect of exchange rate changes | -313.89%-77M | -342.11%-46M | 180.00%8M | -314.29%-30M | -175.00%-9M | 289.47%36M | 0.00%19M | 52.38%-10M | 177.78%14M | 1,100.00%12M |
End cash Position | -0.48%624M | -0.48%624M | 20.66%619M | 3.19%614M | -2.74%639M | -2.34%627M | -2.34%627M | -37.59%513M | -24.68%595M | -5.33%657M |
Free cash flow | -169.57%-400M | -798.08%-467M | 41.75%146M | -162.11%-59M | -104.65%-20M | 31.58%575M | -126.53%-52M | 28.75%103M | 23.38%95M | 411.90%430M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |